Interesting Images223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate CancerWang, Jiaqiong MD, PhD; Kuker, Russ MD; Serafini, Aldo MDAuthor Information From the Division of Nuclear Medicine, Department of Radiology, Miller School of Medicine, University of Miami Hospital/Jackson Memorial Hospital, Miami, FL. Received for publication February 21, 2020; revision accepted May 9, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Jiaqiong Wang, MD, PhD, Division of Nuclear Medicine, Department of Radiology, Miller School of Medicine, University of Miami Hospital/Jackson Memorial Hospital. Nuclear Medicine, Central 248 JMH, 1611 NW 12 Ave, Miami, FL 33136. E-mail: email@example.com. Clinical Nuclear Medicine: November 2020 - Volume 45 - Issue 11 - p e486-e488 doi: 10.1097/RLU.0000000000003168 Buy Metrics Abstract A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient’s prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.